Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-FcRH5 antibody-drug conjugate DFRF4539A

An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FcRH5; CD307; FCRL5; IRTA2; BXMAS1) and conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, via the protease-labile linker maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (MC-VC-PABC), with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of anti-FcRH5 ADC DFRF4539A selectively binds to FcRH5 expressed on the surface of myeloma cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis. FcRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.
Synonym:ADC DFRF4539A
anti-FcRH5 ADC DFRF4539A
Code name:DFRF4539A
RG 7598
RG-7598
RG7598
Search NCI's Drug Dictionary